Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Tamborrini, Marco ^a   Mueller, Markus S ^a   Stoffel, Sabine A ^b   Westerfeld, Nicole ^b   Vogel, Denise ^a   Boato, Francesca ^c   Zurbriggen, Rinaldo ^b   Robinson, John A ^c   Pluschke, Gerd ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Pevion Biotech Ltd   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3; MONOCLONAL ANTIBODY; PARASITE ANTIBODY; PARASITE ANTIGEN; PHOSPHATIDYLETHANOLAMINE; PROTEIN FB 12; PROTEIN FB 13; PROTEIN FB 14; PROTEIN FB 16; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIROSOME VACCINE; CARRIER PROTEIN; CYCLOPEPTIDE; MEROZOITE SURFACE PROTEIN 3, PLASMODIUM; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; SUBUNIT VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOSTIMULATION; LOW DRUG DOSE; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN STABILITY; RABBIT; VACCINATION; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; ORTHOMYXOVIRUS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CARRIER PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; PEPTIDES, CYCLIC; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RABBITS; VACCINES, SUBUNIT; VACCINES, VIROSOME; VIRAL PROTEINS;

EID: 76749147428     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-314     Document Type: Article

References (35)

1. Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine. R Wang Y Charoenvit TM Daly CA Long G Corradin SL Hoffman, Immunol Lett 1996 53 83 93 10.1016/S0165-2478(96)02610-7 9024983
2. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines. ME Patarroyo MA Patarroyo, Acc Chem Res 2008 3 377 386 10.1021/ar700120t
3. Synthetic peptide vaccines and the search for neutralization B cell epitopes. MHV Van Regenmortel, The Open Vaccine Journal 2009 2 33 44
4. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. SL Okitsu O Silvie N Westerfeld M Curcic AR Kammer MS Mueller RW Sauerwein JA Robinson B Genton D Mazier R Zurbriggen G Pluschke, PLoS One 2007 2 1278 10.1371/journal.pone.0001278 18060072
5. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. F Pöltl-Frank R Zurbriggen A Helg F Stuart J Robinson R Glück G Pluschke, Clin Exp Immunol 1999 117 496 503 10.1046/j.1365-2249.1999.00989.x 10469053
6. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. R Moreno L Jiang K Moehle R Zurbriggen R Glück JA Robinson G Pluschke, Chembiochem 2001 2 838 843 10.1002/1439-7633(20011105)2:11<838::AID-CBIC8383.0.CO;2-4 11948870
7. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. MS Mueller A Renard F Boato D Vogel M Naegeli R Zurbriggen JA Robinson G Pluschke, Infect Immun 2003 71 4749 4758 10.1128/IAI.71.8.4749-4758.2003 12874357
8. A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. B Pfeiffer E Peduzzi K Moehle R Zurbriggen R Glück G Pluschke JA Robinson, Angew Chem Int Ed Engl 2003 42 2368 2371 10.1002/anie.200250348 12783498
9. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. SL Okitsu U Kienzl K Moehle O Silvie E Peduzzi MS Mueller RW Sauerwein H Matile R Zurbriggen D Mazier JA Robinson G Pluschke, Chem Biol 2007 14 577 587 10.1016/j.chembiol. 2007.04.008 17524988
10. Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites. SL Okitsu F Boato MS Mueller DB Li D Vogel N Westerfeld R Zurbriggen JA Robinson G Pluschke, Peptides 2007 28 2051 2060 10.1016/j.peptides.2007.08.007 17875342
11. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. B Genton G Pluschke L Degen AR Kammer N Westerfeld SL Okitsu S Schroller P Vounatsou MM Mueller M Tanner R Zurbriggen, PLoS One 2007 2 1018 10.1371/journal.pone.0001018 17925866
12. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. FM Thompson DW Porter SL Okitsu N Westerfeld D Vogel S Todryk I Poulton S Correa C Hutchings T Berthoud S Dunachie L Andrews JL Williams R Sinden SC Gilbert G Pluschke R Zurbriggen AV Hill, PLoS One 2008 3 1493 10.1371/journal.pone.0001493 18231580
13. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. PA Bovier T Farinelli L Loutan, Vaccine 2005 23 2424 2429 10.1016/j.vaccine.2004.11.024 15752828
14. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. O Mayorga Pérez C Herzog M Zellmeyer A Loisiga G Frösner M Egger, J Infect Dis 2003 188 671 677 10.1086/377309 12934183
15. Truncation of merozoite surface protein 3 disrupts its trafficking and that of acidic-basic repeat protein to the surface of Plasmodium falciparum merozoites. KE Mills JA Pearce BS Crabb AF Cowman, Mol Microbiol 2002 43 1401 1411 10.1046/j.1365-2958.2002.02834.x 11952894
16. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. C Oeuvray H Bouharoun-Tayoun H Gras-Masse E Bottius T Kaidoh M Aikawa MC Filgueira A Tartar P Druilhe, Blood 1994 84 1594 1602 8068948
17. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. M Theisen S Soe C Oeuvray AW Thomas J Vuust S Danielsen S Jepsen P Druilhe, Infect Immun 1998 66 11 17 9423833
18. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. P Druilhe F Spertini D Soesoe G Corradin P Mejia S Singh R Audran A Bouzidi C Oeuvray C Roussilhon, PLoS Med 2005 2 344 10.1371/journal.pmed.0020344 16262450
19. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. R Audran M Cachat F Lurati S Soe O Leroy G Corradin P Druilhe F Spertini, Infect Immun 2005 73 8017 8026 10.1128/IAI.73.12.8017-8026.2005 16299295
20. Human malaria in immunocompromised mice: an in vivo model to study defence mechanisms against Plasmodium falciparum. E Badell C Oeuvray A Moreno S Soe N van Rooijen A Bouzidi P Druilhe, J Exp Med 2000 192 1653 1659 10.1084/jem.192.11.1653 11104807
21. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. C Oeuvray M Theisen C Rogier JF Trape S Jepsen P Druilhe, Infect Immun 2000 68 2617 2620 10.1128/IAI.68.5.2617-2620.2000 10768952
22. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. D Dodoo M Theisen JA Kurtzhals BD Akanmori KA Koram S Jepsen FK Nkrumah TG Theander L Hviid, J Infect Dis 2000 181 1202 1205 10.1086/315341 10720556 (Pubitemid 30194517)
23. Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. FH Osier SD Polley T Mwangi B Lowe DJ Conway K Marsh, Parasite Immunol 2007 29 387 394 10.1111/j.1365-3024. 2007.00951.x 17650180
24. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. LJ Carvalho FA Alves C Bianco Jr SG Oliveira GM Zanini S Soe P Druilhe M Theisen JA Muniz CT Daniel-Ribeiro, Clin Diagn Lab Immunol 2005 12 242 248 15699417
25. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. H Hisaeda A Saul JJ Reece MC Kennedy CA Long LH Miller AW Stowers, J Infect Dis 2002 185 657 664 10.1086/339187 11865423
26. The assessment of antibody affinity distribution by thiocyanate elution: a simple dose-response approach. MU Ferreira AM Katzin, J Immunol Methods 1995 187 297 305 10.1016/0022-1759(95)00186-4 7499889
27. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. C Oeuvray H Bouharoun-Tayoun H Gras-Masse E Bottius T Kaidoh M Aikawa MC Filgueira A Tartar P Druilhe, Blood 1994 84 1594 1602 8068948
28. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. W Huber I Felger H Matile HJ Lipps S Steiger HP Beck, Mol Biochem Parasitol 1997 87 231 234 10.1016/S0166-6851(97)00067-4 9247935
29. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). DJ McColl RF Anders, Mol Biochem Parasitol 1997 90 21 31 10.1016/S0166-6851(97)00130-8 9497029
30. The alanin-rich heptad repeats are intact in the processed form of Plasmodium falciparum MSP3. JA Pearce AN Hodder RF Anders, Exp Parasitol 2004 108 186 189 10.1016/j.exppara.2004.07.017 15582517
31. Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1. S James K Moehle A Renard MS Mueller D Vogel R Zurbriggen G Pluschke JA Robinson, Chembiochem 2006 7 1943 1950 10.1002/cbic.200600357 17068840
32. Influenza in East Africa, 1969-70. D Montefiore SG Drozdov GW Kafuko OA Fayinka A Soneji, Bull World Health Organ 1970 2 269 273
33. Cellular and humoral responses to tetanus vaccination in Gabonese children. E van Riet K Retra AA Adegnika CM Jol-van der Zijde HW Uh B Lell S Issifou PG Kremsner M Yazdanbakhsh MJ van Tol FC Hartgers, Vaccine 2008 29-30 3690 3695 10.1016/j.vaccine.2008.04.067
34. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. T Chotpitayasunondh U Thisyakorn C Pancharoen S Pepin N Nougarede, PLoS One 2008 12 4028 10.1371/journal.pone.0004028
35. Antigen-induced somatic diversification of rabbit IgH genes: gene conversion and point mutation. CR Winstead SK Zhai P Sethupathi KL Knight, J Immunol 1999 162 6602 6612 10352277